Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

An acute com­pe­ti­tion is emerg­ing among drug de­vel­op­ers look­ing at a rare neu­ro­log­i­cal dis­or­der known as chron­ic in­flam­ma­to­ry de­myeli­nat­ing polyneu­ropa­thy, or CIDP, and Wall Street an­a­lysts are tak­ing note.

At the Amer­i­can Acad­e­my of Neu­rol­o­gy’s an­nu­al meet­ing this week, ar­genx and Sanofi both re­leased tri­al up­dates for their CIDP pro­grams. And though ar­genx has at least a three-year lead with its drug Vyv­gart al­ready ap­proved in an­oth­er in­di­ca­tion, an­a­lysts ex­pect Sanofi and oth­ers — par­tic­u­lar­ly Di­anthus Ther­a­peu­tics and Im­muno­vant — to prove wor­thy com­peti­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER